SCHEMBL1156584

SCHEMBL1156584

NC(=O)c1c(C(=O)O)[nH]c2ccc([N+](=O)[O-])cc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.68
ALDH1A1 P00352 3/20 0.68
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
PKM P14618 1/20 0.68
NPY1R P25929 1/20 0.68
NPY2R P49146 1/20 0.68
MAPT P10636 4/20 0.62
GAA P10253 2/20 0.57
KDM4E B2RXH2 1/20 0.57
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CA12 O43570 2/20 0.48
CA9 Q16790 2/20 0.48
HTT P42858 1/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
PARP1 P09874 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28552503 0.89 KMT2A (0.57) POLBALDH1A1MEN1KMT2APKM
SCHEMBL6847834 0.81 ALDH1A1 (1.00) POLBALDH1A1MEN1KMT2APKM
SCHEMBL18092607 0.80 MEN1 (0.72) POLBALDH1A1MEN1KMT2APKM
SCHEMBL28808509 0.80 MEN1 (0.72) POLBALDH1A1MEN1KMT2APKM
SCHEMBL1155981 0.78 NGFR (0.53) POLBALDH1A1MEN1KMT2APKM
SCHEMBL18092674 0.77 MAPT (0.81) POLBALDH1A1MEN1KMT2APKM
SCHEMBL5327852 0.77 ALDH1A1 (0.68) POLBALDH1A1MEN1KMT2APKM
SCHEMBL5889822 0.77 ALDH1A1 (0.71) POLBALDH1A1MEN1KMT2APKM
SCHEMBL2235162 0.77 ALDH1A1 (0.71) POLBALDH1A1MEN1KMT2APKM
SCHEMBL3944802 0.77 MAPT (1.00) POLBALDH1A1MEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776106-B1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMA (US) 2013-08-07 EP disclosed
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-20060074076-A1 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C POLB 4878/4885ALDH1A1 3826/4885MEN1 3121/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C POLB 4878/4885ALDH1A1 3826/4885MEN1 3121/4885
US-20060074076-A1 Heterocyclic derivatives for modulation of calcium channels CACNA1D, ORAI1, CACNA1C POLB 4878/4885ALDH1A1 3826/4885MEN1 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.